Ascentage Grosses $126.4m In First Biopharma IPO In The US For 2025
The China/US hematologic cancer-focused firm said the offering should give it runway into 2028, perhaps time enough to bring its top two pipeline assets to market in the US.
The China/US hematologic cancer-focused firm said the offering should give it runway into 2028, perhaps time enough to bring its top two pipeline assets to market in the US.